Australia markets closed

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.9500+0.0100 (+0.34%)
At close: 03:59PM EDT
3.1500 +0.20 (+6.78%)
Pre-market: 04:57AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.9400
Open2.9300
Bid0.0000 x 1100
Ask0.0000 x 1100
Day's range2.7866 - 3.0300
52-week range1.8600 - 9.0100
Volume17,249
Avg. volume792,175
Market cap7.44M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-22.0000
Earnings date08 Nov 2023 - 13 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est68.00
  • GlobeNewswire

    Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

    Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry into the BB-301 Phase 1b/2a Clinical Treatment Study Successful Closing of a $30.9 M Public Offering HAYWARD, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or

  • GlobeNewswire

    Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

    HAYWARD, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") “Silence and Replace” platform, today announced it closed its previously announced underwritten public offering of 15,544,041 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof)

  • GlobeNewswire

    Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

    HAYWARD, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") “Silence and Replace” platform, today announced the pricing of its underwritten public offering of 15,544,041 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanyin